Who is this study for: Patients with primary refractory or relapsed Hodgkin lymphoma
Status: Recruiting
Start Date: November 2, 2021
Intervention Type: Procedure, Biological, Radiation, Drug
Study Drugs: Cytarabine, Melphalan, Podofilox, Etoposide, Basiliximab, Carmustine
Phase: Phase 2